← Banking With Billy News

Capricor Therapeutics responded to FDA briefing materials ahead of the July 29 advisory committee meeting on Deramiocel for Duchenne muscular dystrophy. The pan

BWB News TV • 2026-07-27 15:26 UTC • By Billy Odell Tucker-Robinson
Capricor Therapeutics responded to FDA briefing materials ahead of the July 29 advisory committee meeting on Deramiocel for Duchenne muscular dystrophy. The pan
Capricor Therapeutics responded to FDA briefing materials ahead of the July 29 advisory committee meeting on Deramiocel for Duchenne muscular dystrophy. The panel’s view could shape the therapy’s regulatory path and Capricor’s outlook.
Share this article
𝕏 X / Twitter Facebook LinkedIn WhatsApp
📚 More from Billy’s World
📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly